Centene Raises 2026 EPS Guidance, but Structural HBR Risks Persist

What happened

Centene raised its 2026 EPS guidance, citing its integrated healthcare model, AI-driven operations, and improving Medicaid margins, according to a Zacks article. However, the company's deep-seated challenges remain: ACA risk-adjustment errors, elevated medical cost ratios, and the looming threat of BBBA Medicaid cuts that could pressure earnings beyond 2026. The third-quarter 2025 consolidated HBR stood at 92.7%, well above the low-90% target, and the $6.7 billion goodwill impairment underscores the fragility of the earnings recovery narrative. While the guidance raise provides near-term optimism, the DeepValue master report maintains a WAIT rating, requiring sustained HBR improvement below 90% for two consecutive quarters before considering entry. The core question is whether the 2026 rate hikes and cost initiatives can structurally lower HBR, or if elevated morbidity and policy headwinds will cap margin recovery.

Implication

The raised guidance could sustain the stock's recent recovery toward the $50 level, potentially tempting value-oriented investors. However, the DeepValue analysis shows that even after the raise, Centene trades at only 3.8x EV/EBITDA and 1.1x book, reflecting deeply impaired earnings power. The key risk is that the ACA and Medicaid HBR remain in the mid-90s despite pricing actions, forcing further impairments or a credit downgrade. Until the company demonstrates two consecutive quarters of HBR reduction to the high-80s or low-90s, the margin of safety is thin and downside to $35 is plausible. For patient investors, a better entry would be near the high-$30s low, or after the release of 1H26 HBR data confirms the turnaround thesis.

Thesis delta

The guidance raise shifts the near-term narrative from crisis to stabilization, but it does not resolve the structural HBR overhang. The DeepValue thesis remains unchanged: wait for proof of sustained HBR improvement below 90% before allocating. Until then, the stock lacks asymmetric upside and carries material downside risk from policy and utilization headwinds.